Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
Amicus Therapeutics has announced they have begun a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for their drug combination, AT-GAA, to treat late onset Pompe disease (LOPD).